Prime Medicine
Paula Wiafe has extensive work experience in the biotechnology and pharmaceutical industries. Paula is currently employed at Prime Medicine, Inc. as a Scientist, specializing in the testing and management of CMC QC. Paula joined the company in August 2022.
Prior to their current role, Paula worked at BioAgilytix Boston (previously Cambridge Biomedical Inc.) as a Scientist from December 2020 to August 2022.
Paula also has experience at Eurofins BioPharma Product Testing (DACH), where they served as a Staff Scientist from November 2016 to December 2020 and as an Associate Scientist-Biotech from November 2014 to October 2016.
Paula's career began at the Biochemistry Department, where they worked as a Student Researcher from August 2009 to 2012.
Paula Wiafe completed their education in a chronological order. Paula obtained their Bachelor of Science degree in Biochemistry and Molecular Biology from Michigan State University between 2008 and 2012. Following that, they pursued a Master of Public Health (MPH) degree in Public Health at the University of Missouri-Columbia from 2012 to 2014.
In addition to their academic qualifications, Paula Wiafe has also obtained several certifications. In 2021, they earned certifications in diverse areas such as Managing Stress for Positive Change, How to Be Both Assertive and Likable, How to Train Your Brain For Happiness, Time Management Fundamentals, Design Thinking: Understanding the Process, Learning Excel 2016, Developing Your Creativity as a Leader, Diversity, Inclusion, and Belonging, and Spotting Misinformation Online. These certifications were obtained from LinkedIn.
This person is not in the org chart
This person is not in any offices
Prime Medicine
4 followers
Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations. We envision a world where this technology can cure, halt, and ultimately prevent genetic diseases, providing lifelong benefit to patients. Prime Medicine offers the opportunity to shape the future of gene editing and transform how medicines are used to treat disease. Realizing the promise of Prime Editing requires a talented team with diversity of viewpoints and expertise. We’re building a group of dedicated, scientifically curious individuals who are passionate about helping patients live longer, healthier lives.